{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T03:51:27Z","timestamp":1791172287984,"version":"4.1.0"},"reference-count":92,"publisher":"Wiley","issue":"12P2","license":[{"start":{"date-parts":[[2012,1,6]],"date-time":"2012-01-06T00:00:00Z","timestamp":1325808000000},"content-version":"vor","delay-in-days":1497,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2007,12]]},"abstract":"<jats:p>Inhibitors of monoamine oxidase (MAO) with selectivity and specificity for MAO type B prolong the activity of both endogenously and exogenously derived dopamine, making them an option either as monotherapy in early Parkinson's disease or as adjunctive therapy in patients treated with levodopa who are experiencing motor complications. In addition to symptomatic benefits, experimental data suggest that MAO\u2010B inhibitors may be neuroprotective through MAO\u2010B inhibition and other mechanisms that have yet to be clearly defined. The two available MAO\u2010B inhibitors approved for use in the United States, rasagiline and selegiline, each provide symptomatic relief as monotherapy and as adjunctive therapy, and have shown potential disease\u2010modifying effects in experimental models and clinical studies. Selegiline in a conventional tablet formulation is less bioavailable than rasagiline, resulting in limited potency. It also has amphetamine metabolites that may produce adverse effects and interfere with any putative disease\u2010modifying effects. The oral disintegrating tablet formulation of selegiline allows pregastric absorption, minimizing first\u2010pass metabolism, thereby increasing selegiline bioavailability and reducing the concentration of amphetamine metabolites. Rasagiline, more potent than selegiline, exhibits disease\u2010modifying effects in experimental models and lacks amphetamine metabolites. Both the symptomatic and potential disease\u2010modifying effects of rasagiline are under investigation. A third agent with MAO\u2010B inhibition properties, safinamide, is in phase III development. Although not yet approved, safinamide may offer the added advantage of combined MAO\u2010B and dopamine reuptake inhibition.<\/jats:p>","DOI":"10.1592\/phco.27.12part2.174s","type":"journal-article","created":{"date-parts":[[2007,11,27]],"date-time":"2007-11-27T09:12:48Z","timestamp":1196154768000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":133,"title":["Monoamine Oxidase\u2010B Inhibition in the Treatment of Parkinson's Disease"],"prefix":"10.1002","volume":"27","author":[{"given":"Hubert H.","family":"Fernandez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack J.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,6]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.suppl_5.S1"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000206363.57955.1b"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.42.6.1142"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.27.12part2.155S"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.2147\/nedt.2007.3.1.161"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8257(199909)14:5<836::AID-MDS1018>3.0.CO;2-0"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21273"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ede.0000229445.90471.5e"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.13.1653"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.10609"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.3.358"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.27.12part2.161S"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16305-8"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01246958"},{"key":"e_1_2_1_16_2","first-page":"49","article-title":"Molecular neuroanatomy of MAO\u2010A and MAO\u2010B","volume":"32","author":"Saura MJ","year":"1990","journal-title":"J Neural Transm"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270005277935"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(84)91293-2"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199301213280305"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.2510160703"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199733020-00002"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200009000-00006"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8257(199903)14:2<246::AID-MDS1008>3.0.CO;2-P"},{"key":"e_1_2_1_24_2","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S0022-3565(25)27553-X","article-title":"Effects of hydroxy\u2010amphetamine on the function of the sympathetic nervous system in normotensive subjects","volume":"155","author":"Gill JR","year":"1967","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.63.2.228"},{"key":"e_1_2_1_26_2","unstructured":"Somerset Pharmaceuticals.Eldepryl (selegiline) prescribing information. Tampa FL;1998."},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006289852"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1998.tb06876.x"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-003-0036-4"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0703826"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21048"},{"issue":"3","key":"e_1_2_1_32_2","first-page":"A345","article-title":"Tyramine challenge to assess the safety of rasagiline monotherapy in a placebo\u2010controlled multicenter trial for early Parkinson's disease (the TEMPO study) [abstract]","volume":"56","author":"Parkinson Study Group.","year":"2001","journal-title":"Neurology"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.10191"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.39.8.1109"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(77)90725-5"},{"key":"e_1_2_1_36_2","first-page":"646","article-title":"Deprenyl versus placebo in Parkinson disease: a double\u2010blind study","volume":"87","author":"Lieberman AN","year":"1987","journal-title":"N Y State J Med"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.311.7020.1602"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.316.7139.1191"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000204007.46190.54"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(84)90700-3"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/311467a0"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410260518"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.1997.68010033.x"},{"key":"e_1_2_1_44_2","first-page":"45","article-title":"(\u2010)\u2010Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase","volume":"48","author":"Tatton WG","year":"1996","journal-title":"J Neural Transm"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.490380109"},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(01)01548-5"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2003.10.067"},{"key":"e_1_2_1_48_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.317.7153.252"},{"key":"e_1_2_1_49_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0705962"},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1971122part1245"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2006.00742.x"},{"key":"e_1_2_1_52_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000215250.82576.87"},{"key":"e_1_2_1_53_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20036"},{"key":"e_1_2_1_54_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079906X167697"},{"key":"e_1_2_1_55_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.59.12.1937"},{"key":"e_1_2_1_56_2","first-page":"2498","article-title":"Levodopa and the progression of Parkinson's disease","volume":"35","author":"Parkinson Study Group.","year":"2004","journal-title":"N Engl J Med"},{"key":"e_1_2_1_57_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.61.4.561"},{"key":"e_1_2_1_58_2","unstructured":"RascolO. OlanowW.ADAGIO: A prospective double\u2010blind delayed\u2010start study to examine a potential disease\u2010modifying effect of rasagiline in Parkinson's disease.Poster presentation at the 10th international congress of the Movement Disorder Society Kyoto Japan October 28\u2010November 2 2006."},{"key":"e_1_2_1_59_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.62.2.241"},{"key":"e_1_2_1_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)71083-7"},{"key":"e_1_2_1_61_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000210692.95595.1c"},{"key":"e_1_2_1_62_2","doi-asserted-by":"publisher","DOI":"10.1007\/s007020170018"},{"key":"e_1_2_1_63_2","doi-asserted-by":"publisher","DOI":"10.1007\/s007020050182"},{"key":"e_1_2_1_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-3057(97)00603-5"},{"key":"e_1_2_1_65_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-7091-6499-0_29"},{"key":"e_1_2_1_66_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-004-0481-5"},{"key":"e_1_2_1_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(98)00929-7"},{"key":"e_1_2_1_68_2","doi-asserted-by":"publisher","DOI":"10.1007\/s007020170012"},{"key":"e_1_2_1_69_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-004-0254-4"},{"key":"e_1_2_1_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2004.03.005"},{"key":"e_1_2_1_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2003.08.005"},{"key":"e_1_2_1_72_2","doi-asserted-by":"publisher","DOI":"10.1007\/s007020200038"},{"key":"e_1_2_1_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2004.10.016"},{"key":"e_1_2_1_74_2","first-page":"171","article-title":"Neurotoxins induce apoptosis in dopamine neurons: protection by N\u2010propargylamine\u20101* (R)\u2010 and (S)\u2010aminoindan, rasagiline and TV1022","volume":"60","author":"Maruyama W.","year":"2000","journal-title":"J Neural Transm"},{"key":"e_1_2_1_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0892-0362(02)00221-0"},{"key":"e_1_2_1_76_2","first-page":"495","article-title":"Pharmacology of rasagiline (N\u2010propargyl\u2010*1R\u2010aminoindan)","volume":"80","author":"Finberg JP","year":"1999","journal-title":"Adv Neurol"},{"key":"e_1_2_1_77_2","first-page":"562","article-title":"N\u2010propargyl\u20101(R)\u2010aminoindan (TVP\u20101012), a putative neuroprotective agent, enhances in vitro neuronal survival after glutamate toxicity [abstract]","volume":"21","author":"Yoles E.","year":"1995","journal-title":"Proc Am Soc Neurosci"},{"key":"e_1_2_1_78_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4547(19991101)58:3<456::AID-JNR12>3.0.CO;2-S"},{"key":"e_1_2_1_79_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001756-200012180-00007"},{"key":"e_1_2_1_80_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001756-199803090-00026"},{"key":"e_1_2_1_81_2","first-page":"S45","article-title":"Neuroprotective properties of the antiparkinson drug rasagiline and its optical S\u2010isomer [abstract]","volume":"55","author":"Youdim MBH","year":"1999","journal-title":"Neurosci Lett"},{"key":"e_1_2_1_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0047-6374(00)00144-5"},{"key":"e_1_2_1_83_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2002.01047.x"},{"key":"e_1_2_1_84_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1985.tb08891.x"},{"key":"e_1_2_1_85_2","doi-asserted-by":"publisher","DOI":"10.1163\/156856003765764344"},{"key":"e_1_2_1_86_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(03)00535-5"},{"key":"e_1_2_1_87_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2001.00448.x"},{"key":"e_1_2_1_88_2","doi-asserted-by":"publisher","DOI":"10.1096\/fj.04-1916fje"},{"key":"e_1_2_1_89_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(00)00643-3"},{"key":"e_1_2_1_90_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2006.05.014"},{"key":"e_1_2_1_91_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.48.4.1070"},{"issue":"16","key":"e_1_2_1_92_2","first-page":"S104","article-title":"Safety of concomitant therapy with rasagiline and antidepressants in Parkinson's disease [abstract]","volume":"223","author":"Panisset M.","year":"2007","journal-title":"Mov Disord"},{"key":"e_1_2_1_93_2","unstructured":"StocchiF.Phase III data on safinamide in Parkinson's disease.Presented at the 59th annual meeting of the American Academy of Neurology. Boston MA April 28-May 5 2007."}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.27.12part2.174S","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.27.12part2.174S","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:53:36Z","timestamp":1761054816000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.27.12part2.174S"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":92,"journal-issue":{"issue":"12P2","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["10.1592\/phco.27.12part2.174S"],"URL":"https:\/\/doi.org\/10.1592\/phco.27.12part2.174s","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,12]]},"assertion":[{"value":"2012-01-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}